Observational studyInternational journal of urology : official journal of the Japanese Urological Association2025
Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.
Observational study in International journal of urology : official journal of the Japanese Urological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world safety and efficacy of enzalutamide versus darolutamide in nonmetastatic castration-resistant prostate cancer: a multicenter retrospective study.ESMO real world data and digital oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo describe clinical use and outcomes of androgen receptor signaling inhibitors (ARSIs) darolutamide, enzalutamide, and apalutamide in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in Japan.
methodsThis retrospective, observational study examined health claims data from acute care hospitals (Medical Data Vision Co. Ltd. database) in Japan, for patients with nmCRPC initiating an ARSI between February 2020 and April 2023. Key outcomes were time to initial ARSI discontinuation and time to progression to metastatic castration-resistant prostate cancer (mCRPC).
resultsOf 2746 eligible patients, 418 (15%) received darolutamide, 1898 (69%) enzalutamide, and 430 (16%) apalutamide. Median follow-up was 18.1 months for darolutamide, 20.9 months for enzalutamide, and 24.6 months for apalutamide. The proportion of patients initiating treatment at label dose was 78% (darolutamide), 58% (enzalutamide), and 62% (apalutamide). Median times (95% CI) to discontinuation (unadjusted Kaplan-Meier [KM]) were 16.1 months (13.3-21.0) for darolutamide, 12.3 months (11.3-13.3) for enzalutamide, and 7.1 months (5.3-9.7) for apalutamide. The KM-estimated proportions of patients progressing to mCRPC by 24 months (95% CI) were 27% (23-33) for darolutamide, 37% (34-39) for enzalutamide, and 40% (35-45) for apalutamide. The results were consistent across inverse probability of treatment weighting sensitivity analyses.
conclusionsWe observed that a higher proportion of patients receiving darolutamide were likely to stay on treatment longer than patients receiving enzalutamide or apalutamide, and progression to mCRPC appeared to be delayed in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.